TFA Therapeutics, Inc. SEC filings RAJAF
TFA Therapeutics, Inc. has 38 filings in SEC EDGAR's recent list, going back to Dec 6, 2021. Its latest annual report, Form 20-F, was filed on May 15, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Sep 2, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Sep 2, 2026 | Sep 2, 2026 |
| 6-K | Current report (foreign issuer) | Jul 27, 2026 | Jul 27, 2026 |
| 6-K | Current report (foreign issuer) | Jun 25, 2026 | Jun 25, 2026 |
| 20-F | Annual report (foreign issuer) | May 15, 2026 | Dec 31, 2025 |
| NT 20-F | Notification of late filing | Apr 30, 2026 | Dec 31, 2025 |
| 6-K | Current report (foreign issuer) | Nov 26, 2025 | Nov 25, 2025 |
| 20-F/A | Amended annual report (foreign issuer) | Sep 23, 2025 | Dec 31, 2023 |
| 20-F | Annual report (foreign issuer) | Jun 13, 2025 | Dec 31, 2024 |
| NT 20-F | Notification of late filing | Apr 30, 2025 | Dec 31, 2024 |
| 6-K | Current report (foreign issuer) | Dec 6, 2024 | Dec 6, 2024 |
| UPLOAD | Letter from the SEC | Nov 8, 2024 | — |
| CORRESP | Letter to the SEC | Oct 28, 2024 | — |
| 20-F/A | Amended annual report (foreign issuer) | Oct 28, 2024 | Dec 31, 2023 |
| UPLOAD | Letter from the SEC | Sep 4, 2024 | — |
| 20-F | Annual report (foreign issuer) | Jul 5, 2024 | Dec 31, 2023 |
| NT 20-F | Notification of late filing | Apr 30, 2024 | Dec 31, 2023 |
| 6-K | Current report (foreign issuer) | Mar 19, 2024 | Mar 18, 2024 |
| 6-K | Current report (foreign issuer) | Nov 13, 2023 | Sep 30, 2023 |
| 6-K | Current report (foreign issuer) | Sep 28, 2023 | Sep 28, 2023 |
| 20-F | Annual report (foreign issuer) | May 15, 2023 | Dec 31, 2022 |
| NT 20-F | Extension form | Apr 28, 2023 | Dec 31, 2022 |
| 424B4 | Prospectus | Mar 30, 2023 | — |
| EFFECT | Filing | Mar 29, 2023 | — |
| CORRESP | Letter to the SEC | Mar 27, 2023 | — |
| CORRESP | Letter to the SEC | Mar 20, 2023 | — |
| F-1/A | Registration statement | Mar 20, 2023 | — |
| UPLOAD | Letter from the SEC | Mar 17, 2023 | — |
| F-1/A | Registration statement | Mar 6, 2023 | — |
| CORRESP | Letter to the SEC | Jan 20, 2023 | — |
| F-1 | Registration statement (foreign issuer) | Jan 20, 2023 | — |
| UPLOAD | Letter from the SEC | Dec 21, 2022 | — |
| DRSLTR | Filing | Dec 8, 2022 | — |
| DRS/A | Filing | Dec 8, 2022 | — |
| UPLOAD | Letter from the SEC | Oct 19, 2022 | — |
| DRSLTR | Filing | Sep 20, 2022 | — |
| DRS/A | Filing | Sep 20, 2022 | — |
| UPLOAD | Letter from the SEC | Jan 11, 2022 | — |
| DRS | Filing | Dec 6, 2021 | — |
Showing 38 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- RAJAF (OTC)
- Fiscal year ends
- December 31
- Headquarters
- Taipei City
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1885680
- Former names
- Cordyceps Sunshine Biotech Holdings Co., Ltd. (until Jun 25, 2026)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
- Aurora Cannabis Inc ACB
Source: SEC EDGAR filings. This is company-reported data, not investment advice.